- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01245062
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne, 10117
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Allemagne, 69120
- GSK Investigational Site
-
Mannheim, Baden-Wuerttemberg, Allemagne, 68167
- GSK Investigational Site
-
Tuebingen, Baden-Wuerttemberg, Allemagne, 72076
- GSK Investigational Site
-
-
Bayern
-
Muenchen, Bayern, Allemagne, 80804
- GSK Investigational Site
-
Wuerzburg, Bayern, Allemagne, 97080
- GSK Investigational Site
-
-
Niedersachsen
-
Buxtehude, Niedersachsen, Allemagne, 21614
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Allemagne, 45122
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Allemagne, 01307
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Allemagne, 23538
- GSK Investigational Site
-
-
-
-
-
Ciudad Autonoma de Buenos Aires, Argentine, C1121ABE
- GSK Investigational Site
-
-
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australie, 2606
- GSK Investigational Site
-
-
New South Wales
-
Port Macquarie, New South Wales, Australie, 2444
- GSK Investigational Site
-
Waratah, New South Wales, Australie, 2300
- GSK Investigational Site
-
-
Queensland
-
South Brisbane, Queensland, Australie, 4101
- GSK Investigational Site
-
Townsville, Queensland, Australie, 4810
- GSK Investigational Site
-
Woolloongabba, Queensland, Australie, 4102
- GSK Investigational Site
-
-
South Australia
-
Kurralta Park, South Australia, Australie, 5037
- GSK Investigational Site
-
Woodville, South Australia, Australie, 5011
- GSK Investigational Site
-
-
Victoria
-
Heidelberg, Victoria, Australie, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Australie, 3004
- GSK Investigational Site
-
-
-
-
-
Brussels, Belgique, 1200
- GSK Investigational Site
-
Charleroi, Belgique, 6000
- GSK Investigational Site
-
Gent, Belgique, 9000
- GSK Investigational Site
-
Jette, Belgique, 1090
- GSK Investigational Site
-
Kortrijk, Belgique, 8500
- GSK Investigational Site
-
Leuven, Belgique, 3000
- GSK Investigational Site
-
Wilrijk, Belgique, 2610
- GSK Investigational Site
-
Yvoir, Belgique, 5530
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- GSK Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- GSK Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- GSK Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- GSK Investigational Site
-
London, Ontario, Canada, N6A 4L6
- GSK Investigational Site
-
Oshawa, Ontario, Canada, L1G 2B9
- GSK Investigational Site
-
Ottawa, Ontario, Canada, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- GSK Investigational Site
-
Montreal, Quebec, Canada, H2W 1S6
- GSK Investigational Site
-
-
-
-
-
Boulogne-Billancourt, France, 92100
- GSK Investigational Site
-
Grenoble, France, 38043
- GSK Investigational Site
-
Montpellier, France, 34295
- GSK Investigational Site
-
Nantes, France, 44093
- GSK Investigational Site
-
Paris Cedex 10, France, 75475
- GSK Investigational Site
-
Pierre-Benite cedex, France, 69495
- GSK Investigational Site
-
Rennes, France, 35042
- GSK Investigational Site
-
Tours, France, 37044
- GSK Investigational Site
-
Villejuif, France, 94805
- GSK Investigational Site
-
-
-
-
-
Chelyabinsk, Fédération Russe, 454087
- GSK Investigational Site
-
Magnitogorsk, Fédération Russe, 455001
- GSK Investigational Site
-
Moscow, Fédération Russe, 115478
- GSK Investigational Site
-
St. Petersburg, Fédération Russe, 197758
- GSK Investigational Site
-
-
-
-
-
Athens, Grèce, 11527
- GSK Investigational Site
-
Athens, Grèce, 185 47
- GSK Investigational Site
-
Thessaloniki, Grèce, 564 29
- GSK Investigational Site
-
-
-
-
Lombardia
-
Milano, Lombardia, Italie, 20132
- GSK Investigational Site
-
Milano, Lombardia, Italie, 20133
- GSK Investigational Site
-
Milano, Lombardia, Italie, 20141
- GSK Investigational Site
-
-
Toscana
-
Pisa, Toscana, Italie, 56126
- GSK Investigational Site
-
-
-
-
-
Graz, L'Autriche, 8036
- GSK Investigational Site
-
Wien, L'Autriche, 1090
- GSK Investigational Site
-
-
-
-
-
Oslo, Norvège, 0310
- GSK Investigational Site
-
-
-
-
-
Christchurch, Nouvelle-Zélande, 8011
- GSK Investigational Site
-
Dunedin, Nouvelle-Zélande, 9016
- GSK Investigational Site
-
Newtown, Wellington, Nouvelle-Zélande, 6002
- GSK Investigational Site
-
-
-
-
-
Poznan, Pologne, 61-866
- GSK Investigational Site
-
Warszawa, Pologne, 02-781
- GSK Investigational Site
-
Warszawa, Pologne, 04-125
- GSK Investigational Site
-
-
-
-
-
Aberdeen, Royaume-Uni, AB25 2ZN
- GSK Investigational Site
-
Birmingham, Royaume-Uni, B15 2TH
- GSK Investigational Site
-
Chelmsford, Royaume-Uni, CM1 7ET
- GSK Investigational Site
-
Leeds, Royaume-Uni, LS9 7TF
- GSK Investigational Site
-
London, Royaume-Uni, SW3 6JJ
- GSK Investigational Site
-
London, Royaume-Uni, W1G 6AD
- GSK Investigational Site
-
Manchester, Royaume-Uni, M20 4BX
- GSK Investigational Site
-
Oxford, Royaume-Uni, OX3 7LJ
- GSK Investigational Site
-
Southampton, Royaume-Uni, SO16 6YD
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Royaume-Uni, CB2 2QQ
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Royaume-Uni, HA6 2RN
- GSK Investigational Site
-
-
Surrey
-
Sutton, Surrey, Royaume-Uni, SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Zurich, Suisse, 8091
- GSK Investigational Site
-
-
-
-
-
Goteborg, Suède, SE-413 45
- GSK Investigational Site
-
Linkoping, Suède, SE-581 85
- GSK Investigational Site
-
Lund, Suède, SE-221 85
- GSK Investigational Site
-
Stockholm, Suède, SE-171 76
- GSK Investigational Site
-
Uppsala, Suède, SE-751 85
- GSK Investigational Site
-
-
-
-
-
Hradec Kralove, Tchéquie, 500 05
- GSK Investigational Site
-
Ostrava, Tchéquie, 708 52
- GSK Investigational Site
-
Praha 2, Tchéquie, 128 08
- GSK Investigational Site
-
Zlin, Tchéquie, 76275
- GSK Investigational Site
-
-
-
-
-
Dnepropetrovsk, Ukraine, 49102
- GSK Investigational Site
-
Kharkiv, Ukraine, 61070
- GSK Investigational Site
-
Kyiv, Ukraine, 03022
- GSK Investigational Site
-
Kyiv, Ukraine, 03115
- GSK Investigational Site
-
Lviv, Ukraine, 79031
- GSK Investigational Site
-
Sumy, Ukraine, 40005
- GSK Investigational Site
-
Sympheropol, Ukraine, 95023
- GSK Investigational Site
-
Ternopil, Ukraine, 46023
- GSK Investigational Site
-
Uzhgorod, Ukraine, 88017
- GSK Investigational Site
-
-
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85724-5024
- GSK Investigational Site
-
-
Florida
-
Fort Myers, Florida, États-Unis, 33916
- GSK Investigational Site
-
-
Georgia
-
Athens, Georgia, États-Unis, 30607
- GSK Investigational Site
-
Marietta, Georgia, États-Unis, 30060
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- GSK Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, États-Unis, 70006
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- GSK Investigational Site
-
-
New Jersey
-
Morristown, New Jersey, États-Unis, 07962-1956
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43210
- GSK Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, États-Unis, 29210
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, États-Unis, 37404
- GSK Investigational Site
-
Memphis, Tennessee, États-Unis, 38120
- GSK Investigational Site
-
Nashville, Tennessee, États-Unis, 37203
- GSK Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- ≥18 years of age
- Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
- Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Adequate screening organ function
Exclusion Criteria:
- Any prior use of BRAF inhibitors or MEK inhibitors.
- Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
- History of another malignancy. Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
- Brain metastases with the following exceptions that are ALL confirmed by the GSK Medical Monitor:
All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to randomization (must be documented with two consecutive MRI or CT scans using contrast), and asymptomatic with no corticosteroids requirement for ≥ 30 days prior to randomization, and no enzyme-inducing anticonvulsants for ≥ 30 days prior to randomization
History or evidence of cardiovascular risk including any of the following:
- QTcB ≥ 480 msec.
- History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible
- History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
- History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association
- History of interstitial lung disease or pneumonitis
History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):
- History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes).
- Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
- Evidence of new optic disc cupping.
- Intraocular pressure > 21 mm Hg as measured by tonography
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: GSK1120212
MEK inhibitor
|
Inhibiteur de MEK
|
Comparateur actif: Chemotherapy
Investigator Choice of DTIC or paclitaxel
|
Investigator Choice of DTIC or paclitaxel
|
Expérimental: Crossover
MEK inhibitor after documented progression on Chemotherapy Arm
|
Inhibiteur de MEK
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death.
PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment.
Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Progression-free Survival in All Participants
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed and BRIC-assessed PFS were summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Intend-To-Treat (ITT) Population included all randomized participants regardless of whether or not treatment was administered.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Overall Survival in All Participants
Délai: Day 1 until death due to any cause (average of 20.3 months)
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
|
Day 1 until death due to any cause (average of 20.3 months)
|
Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases
Délai: Day 1 until death due to any cause (average of 20.3 months)
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
NA indicates data was not available.
|
Day 1 until death due to any cause (average of 20.3 months)
|
Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of Participants With OR as Assessed by the Investigator and Independent Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (disappearance of all extranodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all extranodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of Participants With OR Following Cross-over to Trametinib
Délai: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
OR is defined as the number of participants with evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib.
The evaluation was carried out by the Investigator per RECIST, Version 1.1.
Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT.
Only participants who received at least one dose of Trametinib were included in this population.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause.
DoR for the investigator-assessed (INVA) response data were summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause.
DoR for the independently-assessed (INDA) response data were summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR for the INVA response data was summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review
Délai: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR for the INDA response data was summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator
Délai: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
PFS Following Cross-over to Trametinib as Assessed by the Investigator
Délai: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death.
PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin Cancer Res. 2016 Feb 1;22(3):567-74. doi: 10.1158/1078-0432.CCR-15-0321. Epub 2015 Oct 7.
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
- Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.
- Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 2016 May;5(5):806-15. doi: 10.1002/cam4.643. Epub 2016 Jan 27.
- Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol. 2014 Mar;25(3):700-706. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Mélanome
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de protéine kinase
- Tramétinib
Autres numéros d'identification d'étude
- 114267
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur GSK1120212
-
Novartis PharmaceuticalsRésiliéCancerFrance, États-Unis, Pays-Bas, Canada, Taïwan, Corée, République de
-
National Cancer Institute (NCI)Actif, ne recrute pasTumeur solide maligne avancée | Tumeur solide maligne métastatique | Tumeur maligne métastatique dans le foie | Tumeur solide non résécableÉtats-Unis, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupActif, ne recrute pasLeucémie myélomonocytaire juvénile | Neurofibromatose Type 1États-Unis
-
National Cancer Institute (NCI)ComplétéHémangioendothéliome épithélioïde localement avancé | Hémangioendothéliome épithélioïde métastatique | Hémangioendothéliome épithélioïde non résécableÉtats-Unis
-
Jonsson Comprehensive Cancer CenterNovartis; Stand Up To Cancer; Prostate Cancer FoundationActif, ne recrute pasCarcinome métastatique de la prostate | Carcinome de la prostate récurrent | Cancer de la prostate de stade IV | Cancer de la prostate hormono-résistantÉtats-Unis
-
National Cancer Institute (NCI)ComplétéMyélome plasmocytaire réfractaire | Myélome plasmocytaire récurrentCanada
-
National Cancer Institute (NCI)ComplétéStade IV Mélanome Uvéal AJCC v7 | Mélanome uvéal récurrentÉtats-Unis, France, Royaume-Uni
-
National Cancer Institute (NCI)GlaxoSmithKlineComplétéCancer du sein de stade IV | Carcinome mammaire récurrent | Carcinome du sein invasif | Récepteur des œstrogènes négatif | HER2/Neu Négatif | Récepteur de la progestérone négatif | Carcinome du sein triple négatifÉtats-Unis
-
National Cancer Institute (NCI)RésiliéLeucémie myéloïde aiguë récurrente de l'adulte | Leucémie myéloïde aiguë non traitée chez l'adulteÉtats-Unis
-
University of UtahNovartis PharmaceuticalsRecrutementCarcinome pancréatique métastatique | Carcinome pancréatique non résécable | Cancer du pancréas de stade III | Cancer du pancréas de stade IV | Cancer du pancréas de stade IIA | Cancer du pancréas de stade IIB | Cancer du pancréas de stade IIÉtats-Unis